Company - EnVivo

Mission: to discover and develop therapeutics for disorders of the central nervous system (CNS), specifically Alzheimer’s Disease and Schizophrenia.

About Us

EnVivo Pharmaceuticals was founded in 2001 and currently has 38 FTEs. EnVivo has raised ~$63.2M in three funding rounds, $14.9M Series A in October 2002 and $24.3M Series B in September 2004, $24M Series C in September 2006.  Investors include scientific founders, Fidelity Bioscience Group, BBBC Investor Group that includes Baylor College of Medicine, and CoGene BioTech Ventures. EnVivo is currently raising another round of financing to support pre-clinical and clinical development of its lead programs.

EnVivo is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders. CNS disorders account for more hospitalizations, long-term care, and chronic suffering than nearly all other diseases combined. Since age is a risk factor for many CNS disorders, the prevalence of these diseases is increasing as the population ages. The medical need in these disorders is very high as the treatment options available are not satisfactory.

EnVivo was founded by four scientific leaders in neuroscience and genetics. Enabling intellectual property has been exclusively licensed to EnVivo from leading research institutions, including Baylor College of Medicine, in Houston, Texas and the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany.